Patient and donor demographics
| Characteristic . | Data (N = 93) . |
|---|---|
| Median patient age (range), y | 72 (70-78) |
| Male sex, n (%) | 64 (69) |
| Disease, n | |
| NHL | 33 |
| AML | 33 |
| MDS | 17 |
| MPN | 4 |
| CML, second CP | 2 |
| ALL | 2 |
| Other* | 2 |
| rDRI, n (%) | |
| Low | 8 (9) |
| Intermediate | 73 (78) |
| High/very high | 11 (12) |
| NA | 1 (1) |
| HCT-CI, n (%) | |
| 0 | 23 (25) |
| 1-2 | 38 (41) |
| ≥3 | 31 (33) |
| KPS, n (%) | |
| 70-80 | 23 (25) |
| 90 | 52 (56) |
| 100 | 18 (19) |
| Year of transplant, n (%) | |
| 2009-2014 | 39 (42) |
| 2015-2017 | 54 (58) |
| Median donor age (range), y | 43 (16-69) |
| Graft source, n (%) | |
| Bone marrow | 69 (74) |
| Peripheral blood | 24 (26) |
| CMV status, n (%) | |
| R−/D− | 36 (39) |
| R+/D- | 24 (26) |
| R−/D+ | 4 (4) |
| R+/D+ | 27 (29) |
| Missing | 2 (2) |
| Characteristic . | Data (N = 93) . |
|---|---|
| Median patient age (range), y | 72 (70-78) |
| Male sex, n (%) | 64 (69) |
| Disease, n | |
| NHL | 33 |
| AML | 33 |
| MDS | 17 |
| MPN | 4 |
| CML, second CP | 2 |
| ALL | 2 |
| Other* | 2 |
| rDRI, n (%) | |
| Low | 8 (9) |
| Intermediate | 73 (78) |
| High/very high | 11 (12) |
| NA | 1 (1) |
| HCT-CI, n (%) | |
| 0 | 23 (25) |
| 1-2 | 38 (41) |
| ≥3 | 31 (33) |
| KPS, n (%) | |
| 70-80 | 23 (25) |
| 90 | 52 (56) |
| 100 | 18 (19) |
| Year of transplant, n (%) | |
| 2009-2014 | 39 (42) |
| 2015-2017 | 54 (58) |
| Median donor age (range), y | 43 (16-69) |
| Graft source, n (%) | |
| Bone marrow | 69 (74) |
| Peripheral blood | 24 (26) |
| CMV status, n (%) | |
| R−/D− | 36 (39) |
| R+/D- | 24 (26) |
| R−/D+ | 4 (4) |
| R+/D+ | 27 (29) |
| Missing | 2 (2) |
ALL, acute lymphoblastic leukemia; CMV, cytomegalovirus; CML, chronic myelogenous leukemia; CP, chronic phase; D, donor; KPS, Karnofsky Performance Status; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma; R recipient.
Plasmacytoid dendritic cell neoplasm and multiple myeloma.